Discovery of an orally bioavailable reversible covalent SARS-CoV-2 Mpro inhibitor with pan-coronavirus activity Descriptor: (S)-3-((S)-3-cyclobutyl-2-((R)-2-cyclopentyl-N-methyl-2-pivalamidoacetamido)
This document contained a protocol on HIV neutralization utilizing recombinant viruses in HEK-293T cells.Transfection efficiency is monitored by quantifying luciferase expression. Viral supernatants a
aThe 50% inhibitory concentration (IC50) for each compound in the enzymes expressed in insect microsomes.Summary of the effects of Compound A and Compound B.
